Uric Acid Levels In Patients Research Articles

Assessment of Serum Uric Acid Levels in Patients with Acute Myocardial Infarction

Background : Aim of the study was to discover if there is the efficacy of serum uric acid in the prognostication of myocardial infarction subjects. Subjects and Methods: A total of 200 subjects were incorporated into the research. Of them, 74 patients had ST- elevated myocardial infarction, as in 26 subjects they were diagnosed with non-ST elevation myocardial infarction. Of the total of 100 subjects in the study group, there were 70 males and 30 females. A total of 100 healthy individuals as a control group were also incorporated in the study. Serum uric acid was measured on day 0, 3, 7 as well on day 30 of MI. Results: Serum uric acid was calculated on day 0, day 3, and day 7 and on day 30 of the myocardial infarction in the case study group. The mean uric acid levels on day 0 were found to be 6.32 1.45 mg/dl, mean uric acid level on day 3 was found to be 5.98 0.98 mg/dl, mean uric acid level on day 7 was found to be 5.14 2.18 mg/dl and mean uric acid level on day 30 was found to be 4.98 0.44 mg/dl. Conclusion: Serum uric acid stages are elevated in subjects of acute MI in contrast to standard well individuals. Subjects with higher Serum uric acid levels have an elevated probability of transience and it can be measured as a marker of appalling prediction.

Correlation of serum uric acid levels in patients of chronic obstructive pulmonary disease

To evaluate serum uric acid level and correlate with the classification of chronic obstructive pulmonary disease (COPD) severity based on post-bronchodilator FEV1 as per Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. It is an institution based cross-sectional study in which 100 patients were included. Patients were screened for COPD. Clinical profile and oxygen saturation were included. Patients were classified according to GOLD guidelines. We found that serum uric acid level was at higher side in patients of severe and very severe stages of COPD compared to mild and moderate stages. Inverse relationship found between FEV1 and serum uric acid level. We concluded that uric acid is a widely available, easy to interpret, low cost biomarker, suggests the possible role in the identification of COPD patients of increased risk for adverse outcomes that may need early intensive management. Keywords: Chronic obstructive pulmonary disease, GOLD guidelines, Spirometry, Serum uric acid.

Assessment of glycated hemoglobin and uric acid level in polycystic ovarian syndrome in a Tertiary Care Institute of Marathwada region

Introduction: The Polycystic Ovary Syndrome (PCOS) is one of the most common reproductive endocrine disorders, affecting 5–10% of women in the reproductive age. Insulin resistance is the hallmark of this disorder. PCOS has been epidemiologically linked to an increased risk for type 2 diabetes mellitus and cardiovascular diseases. The present study was planned to study glycated hemoglobin (HbA1c) and uric acid level in patients of PCOS. Materials and Methods: The study comprised of 60 women with PCOS as cases and 60 healthy females as controls. HbA1c and uric acid level were measured in all participants. Results: Glycated hemoglobin and serum uric acid were significantly increased in PCOS group and showed positive correlation with body mass index and waist: hip ratio. The prevalence of raised HbA1c was 40% in PCOS women. Conclusion: In our study we found significant alterations in HbA1c and uric acid level in cases of PCOS. Early identification of these changes and timely intervention can reduce morbidity due to type 2 diabetes mellitus and cardiovascular diseases in PCOS. This will help to redefine the paradigms of PCOS care in India. Keywords: Cardiovascular Disease, HbA1c, PCOS, Type 2 Diabetes Mellitus, Uric Acid.

Analysis of Serum Uric Acid Level in Patients with and without Diabetic Nephropathy

Diabetic nephropathy is one of the microvascular complications in type 2 Diabetes Mellitus (DM). Diagnosis of diabeticnephropathy is based on any history of DM, a decrease in Glomerular Estimation Filtrate Rate (eGFR) using the CKD-Epiformula, and albuminuria. The role of serum uric acid level in diabetic nephropathy remains an ongoing debate. Serum uricacid levels may be the cause or the result of diabetic nephropathy. This study aimed to analyze serum uric acid levels inpatients with and without diabetic nephropathy and determine its correlation with diabetic nephropathy. This study wasperformed at Dr. Wahidin Sudirohusodo Hospital, Makassar, by taking the data from the medical record of type 2 DMpatients from January to April 2018. Fifty-nine patients with diabetic nephropathy and 150 patients without diabeticnephropathy participated in this study. An independent T-test and Pearson's correlation test were used for statisticalanalysis. There was a significant difference in uric acid level between patients with and without diabetic nephropathy(9.57±3.42 mg/dL vs. 6.41±2.86 mg/dL, p < 0.001). There was significant correlation between uric acid serum levels with urea(p < 0.001, r=0.585), creatinine (p<0.001, r=0.413) and eGFR (p < 0.001, r=-0.525) in patients with diabetic nephropathy. Uricacid levels in patients with diabetic nephropathy were higher than patients without diabetic nephropathy. Higher levels ofurea and the serum creatinine led to higher levels of serum uric acid. Contrastingly, a lower eGFR rate led to higher levels ofuric acid.

Increased Cerebrospinal Fluid Uric Acid Levels in Guillain-Barré Syndrome.

Uric acid (UA) is a natural scavenger for peroxynitrite and can reflect antioxidant activity and oxidative stress in several neurological disorders. Changes in serum and cerebrospinal fluid (CSF) levels of UA have been reported in patients with multiple sclerosis and neuromyelitis optica spectrum disorders. The levels of UA in CSF are relatively poorly understood in patients with Guillain–Barré syndrome (GBS). It remains unclear whether UA can play an antioxidant role and reflect oxidative stress in GBS. The purpose of this study is to investigate CSF and serum UA levels in patients with GBS and their relationship with clinical characteristics. The CSF and serum UA levels were detected in 43 patients with GBS, including 14 acute inflammatory demyelinating polyneuropathy (AIDP), 6 acute motor axonal neuropathy (AMAN), 13 with acute motor and sensory axonal neuropathy (AMSAN), 7 Miller Fisher syndrome (MFS), and 3 unclassified, and 25 patients with non-inflammatory neurological disorders (NIND) as controls. Moreover, serum UA levels were also detected in 30 healthy controls. The levels of UA were measured using uricase-based methods with an automatic biochemical analyzer. CSF UA levels were significantly increased in patients with GBS (p = 0.011), particularly in patients with AIDP (p = 0.004) when compared with NIND. Among patients with GBS, CSF UA levels were higher in those with demyelination (p = 0.022), although the difference was not significant after multiple testing correction. CSF UA levels in GBS were positively correlated with serum UA levels (r = 0.455, p = 0.022) and CSF lactate (r = 0.499, p = 0.011). However, no significant correlations were found between CSF UA levels and GBS disability scores. There were no significant differences in serum UA levels among GBS, NIND, and healthy controls. These results suggest that CSF UA may be related to the pathogenesis of demyelination in patients with GBS and may be partially determined by serum UA and the impaired blood–nerve barrier.

Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial

BackgroundWe aimed to evaluate the effects of short-term therapy with dapagliflozin on serum uric acid (SUA) and urinary uric acid (UUA) levels in patients with type 2 diabetes.MethodsIn this prospective pilot trial, 8 patients with type 2 diabetes mellitus were assigned to the treatment group with dapagliflozin 10 mg once daily for one week, and 7 subjects with normal glucose tolerance were recruited into the control group. Data of anthropometric measurements, SUA, 24-h UUA, fractional excretion of UA (FEUA), serum lipid parameters and 3-h oral glucose tolerance test (OGTT) were collected in both treatment and control groups; all examinations were repeated after treatment. The area under the curve of glucose (AUCGlu) was calculated to reflect the general glucose levels, while insulin resistance and islet β-cell function were reflected by indexes calculated according to the data obtained from the OGTT.ResultsThe weight and serum lipid parameters showed no differences before and after treatment with dapagliflozin for one week. We found SUA levels decreased from 347.75 ± 7.75 μmol/L before treatment to 273.25 ± 43.18 μmol/L after treatment, with a statistically significant difference (P = 0.001) and was accompanied by a significant increase in FEUA from 0.009 to 0.029 (P = 0.035); there was a linear correlation between SUA and FEUA levels. Glucose control, insulin sensitivity and islet β-cell function were improved to a certain extent. We also found a positive correlation between the decrease in glucose levels and the improvement in islet β-cell function.ConclusionsThe SUA-lowering effect of dapagliflozin could be driven by increasing UA excretion within one week of treatment, and a certain degree of improvement in glucose levels and islet β-cell function were observed.Trial registration ClinicalTrials.gov identifier, NCT04014192. Registered 12 July 2019, https://www.clinicaltrials.gov/ct2/show/NCT04014192:term=NCT04014192&draw=2&rank=1. Yes.

Uric acid as a predictor of endothelial dysfunction in patients with metabolic syndrome.

We conducted a study to examine the association of endothelial dysfunction and oxidative stress with uric acid levels in patients of metabolic syndrome. One hundred and two patients of Metabolic Syndrome (International Diabetes Federation definition) were included in the study. Anthropometric measurements, serum uric acid levels, fasting blood sugar levels and lipid levels, as well as malondialdehyde and reactive nitrogen intermediates were measured after an 8-hour fasting period. Flow mediated vasodilation (FMD) of the brachial artery was measured and endothelial dysfunction was defined as an increase in diameter < 10% post compression. A total of 102 patients were included in the study. Mean uric acid level was 5.49 ± 1.61 mg%. A total of 59 patients in the study had endothelial dysfunction, defined by an abnormal FMD. Patients with an abnormal FMD had higher levels of serum uric acid which was statistically significant (p value = 0.010). Serum RNI and MDA levels were negatively correlated with uric acid, but did not reach statistical significance. Patients with an abnormal FMD had a lower RNI level, but this did not reach statistical significance. Serum MDA levels were significantly higher in patients with an abnormal FMD (p value = 0.038). Uric acid was significantly associated with endothelial dysfunction in patients with metabolic syndrome in our study. It was inversely correlated with serum RNI and MDA levels, but this did not reach statistical significance.

Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study

BackgroundPrevious studies have shown that serum uric acid (UA) levels are correlated with the severity of idiopathic pulmonary arterial hypertension (IPAH) and are predictors of disease prognosis. Still, few studies have explored the value of serum UA in pulmonary arterial hypertension secondary to connective tissue disease (CTD-PAH). This retrospective study aimed to investigate the clinical value of serum UA levels in patients with CTD-PAH.MethodsFifty CTD-PAH patients were enrolled in our study, from which baseline UA levels, respective variations, and additional clinical data were collected. The potential association between baseline UA level and severity of CTD-PAH was investigated. Furthermore, the relationship between baseline UA and survival rate of CTD-PAH patients, as well as between UA variations and survival rate of pulmonary hypertension secondary to connective tissue disease (CTD-PH) patients was discussed.ResultsBaseline serum UA levels were positively correlated with pulmonary vascular resistance (PVR). During the follow-up period, 3 CTD-PAH and 12 CTD-PH patients died. Kaplan-Meier survival curves showed lower survival rate in patients with hyperuricemia than in patients with normouricemia, in both groups (CTD-PAH group p = 0.041, CTD-PH group p = 0.013). Concerning serum UA variations, patients with persistent hyperuricemia showed the lowest survival rate when compared with patients with steady normouricemia (p = 0.01) or patients with decresing serum UA levels, i.e. undergoing from a status of hyperuricemia to a status of normouricemia (p = 0.023).ConclusionBaseline serum UA levels might predict severity of CTD-PAH. Together with baseline values, changes of uric acid level may predict the clinical prognosis of the disease.

Клініко-інструментальна характеристика пацієнтів із хронічною серцевою недостатністю та зниженою фракцією викиду лівого шлуночка залежно від наявності цукрового діабету 2-го типу

Мета роботи – порівняти клініко-інструментальні показники в пацієнтів із хронічною серцевою недостатністю (ХСН) та зниженою фракцією викиду лівого шлуночка (ФВЛШ) залежно від наявності в них цукрового діабету (ЦД) 2-го типу.Матеріали і методи. Проаналізовано 490 історій хвороб пацієнтів, які спостерігалися у відділі серцевої недостатності в період з 2011 до 2018 р., з ХСН ІІ–ІV функціонального класу за NYHA, ФВЛШ ≤ 40 %, віком 40–80 років (медіана (верхній; нижній квартилі) – 64 (56,00; 69,00) роки). До досліджуваної групи увійшли переважно хворі з ішемічною хворобою серця (ІХС) у поєднанні з гіпертонічною хворобою (ГХ) – 403 (82,2 %) пацієнти, з ізольованою ІХС – 55 (11,2 %) та з ізольованою ГХ – 32 (6,6 %). Більшість хворих (278 (56,7 %) осіб) мали постійну форму фібриляції передсердь. Серед досліджуваних було 373 (76,1 %) чоловіки та 117 (23,9 %) жінок. Пацієнтів залучали в дослідження у фазу клінічної компенсації, тобто в еуволемічному стані. Для аналізу всіх пацієнтів з ХСН та зниженою ФВЛШ розподілили на дві групи: в І групу увійшли 338 (69 %) хворих без ЦД, ІІ групу становили 152 (31 %) пацієнти з діагностованим ЦД 2-го типу.Результати та обговорення. За результатами аналізу не виявлено статистично значущих відмінностей між досліджуваними групами за віком пацієнтів, загальними показниками гемодинаміки, середньодобовою частотою серцевих скорочень, функціональним класом ХСН за NYHA, частотою супутнього хронічного обструктивного захворювання легень та тривалістю існування ознак ХСН. Зафіксовано меншу частку пацієнтів з фібриляцією передсердь у ІІ групі, більший показник індексу маси тіла пацієнтів у І групі, показник Е/е΄ та індекс маси міокарда лівого шлуночка були більшими в пацієнтів без супутнього ЦД. У ході дослідження виявили значно вищий рівень сечової кислоти в пацієнтів із супутнім ЦД 2-го типу, за показниками оксидативного стресу та прозапальних маркерів, рівня NT-proBNP та інсуліну статистично значущої різниці між групами не встановлено. Також не спостерігали статистично значущої різниці між групами щодо значень потокозалежної вазодилатації. Показано, що поєднання ІХС та ЦД 2-го типу є основним фактором високої летальності в пацієнтів з ХСН. Утім не виявлено різниці щодо тривалості життя пацієнтів з ХСН та зниженою ФВЛШ із ЦД 2-го типу та без ЦД. Також виявлено статистично значуще гірше виживання пацієнтів з рівнем глікованого гемоглобіну понад 7,4 %.Висновки. П’ятирічна виживаність пацієнтів з ХСН зі зниженою ФВЛШ із ЦД 2-го типу та без ЦД статистично значуще не відрізнялася, тоді як у загальній групі гіршу 5-річну виживаність зареєстровано для тих хворих, які мали показник глікованого гемоглобіну понад 7,4 %.

The prognostic impact of the uric acid level in patients who require cardiovascular intensive care - is serum uric acid a surrogate biomarker for critical patients in the non-surgical intensive care unit?

The prognostic impact of hyperuricemia and the factors that induce hyperuricemia in cardiovascular intensive care patients remain unclear. A total of 3257 emergency department patients were screened, and data for 2435 patients who were admitted to an intensive care unit were analyzed. The serum uric acid level was measured within 15 min of admission. The patients were assigned to a low-uric acid group (uric acid ⩽7.0 mg/dl, n=1595) or a high-uric acid group (uric acid >7.0 mg/dl, n=840) according to their uric acid level on admission. Thereafter, the patients were divided into four groups according to the quartiles of their serum uric acid level (Q1, Q2, Q3 and Q4), and uric acid levels and Acute Physiology and Chronic Health Evaluation II (APACHE II) score. A Kaplan-Meier curve showed a significantly lower 365-day survival rate in a high-uric acid group than in a low-uric acid group, and in Q3 than in Q1 or Q2 and in Q4 than in the other groups. The multivariate logistic regression model for 30-day mortality identified Q4 (odds ratio: 1.856, 95% confidence interval (CI) 1.140-3.022; p=0.013) as an independent predictor of 30-day mortality. The area under the receiver-operating characteristic curve values of the serum uric acid level and APACHE II score for the prediction of 30-day mortality were 0.648 and 0.800, respectively. The category-free net reclassification improvement and integrated discrimination improvement showed that the calculated risk shifted to the correct direction by adding the serum uric acid level to the APACHE II score (0.204, 95% CI 0.065-0.344; p=0.004, and 0.015, 95% CI 0.005-0.025; p=0.004, respectively). The prognosis, including the 365-day mortality, among patients with a high uric acid level and a high APACHE II score was significantly poorer in comparison with other patients. The serum uric acid level, which might be elevated by the various critical stimuli on admission, was an independent predictor in patients who were emergently hospitalized in the intensive care unit. The serum uric acid level is therefore useful as a surrogate biomarker for critical patients in the intensive care unit.

Hyperuricemia as risk factor for cardiovascular disease – what’s new?

A significant number of epidemiological studies have shown that hyperuricemia is highly associated with the risk of developing cardiovascular disease, chronic kidney disease, and diabetes. In this connection, increased attention is required to monitor serum uric acid levels in patients, not only from a rheumatological point of view, but also with regard to reducing cardiovascular and renal risks. This article is a review of studies on the association of hyperuricemia with cardiovascular risk and a new consensus for the management of patients with hyperuricemia and high cardiovascular risk, published in december 2019 by a group of experts of the Russian Medical Society for Arterial Hypertension, which, among other things, includes a management algorithm of this category of patients.

Efficacy of different urinary uric acid indicators in patients with chronic kidney disease

BackgroundMounting studies have shown that hyperuricemia is related to kidney diseases through multiple ways. However, the application of urinary uric acid indicators in patients with reduced renal function is not clear. In this study, we aim to determine the effects of renal function on various indicators reflecting uric acid levels in patients with chronic kidney disease (CKD).MethodsAnthropometric and biochemical examinations were performed in 625 patients with CKD recruited from Dept of Nephrology of Huadong hospital affiliated to Fudan University. Multiple regression analyses were used to study correlations of the estimated glomerular filtration rate (eGFR) with serum uric acid (SUA) and renal handling of uric acid. For further study, smooth curve plots and threshold effect analyses were applied to clarify associations between renal function and uric acid levels.ResultsThe nonlinear relationships were observed between eGFR and urinary uric acid indicators. The obvious inflection points were observed in smooth curve fitting of eGFR and fractional excretion of uric acid (FEur), excretion of uric acid per volume of glomerular filtration (EurGF). In subsequent analyses where levels of eGFR< 15 mL/min/1.73m2 were dichotomized (CKD5a/CKD5b), patients in the CKD5a showed higher levels of FEur and EurGF while lower levels of urinary uric acid excretion (UUA), clearance of uric acid (Cur) and glomerular filtration load of uric acid (FLur) compared with CKD5b group (all P < 0.05). And there was no significant difference of SUA levels between two groups. On the other hand, when eGFR< 109.9 ml/min/1.73 m2 and 89.1 ml/min/1.73 m2, the resultant curves exhibited approximately linear associations of eGFR with Cur and FLur respectively.ConclusionFEur and EurGF showed significantly compensatory increases with decreased renal function. And extra-renal uric acid excretion may play a compensatory role in patients with severe renal impairment to maintain SUA levels. Moreover, Cur and FLur may be more reliable indicators of classification for hyperuricemia in CKD patients.

Evaluating serum uric acid levels in patients with acute myocardial infarction

Background: Elevated levels of serum uric acid are associated with increased cardiovascular morbidity and mortality. However, this association with cardiovascular diseases is still unclear, and perhaps controversial. The objective of study was to assess the serum uric acid level in patients with Acute Myocardial Infarction (AMI).Methods: Sixty patients with AMI were studied in Department of Medicine/ Department of Cardiology, J.A. Group of Hospitals between 2016 -2018.Details of age, sex, smoking, alcohol consumption and history of ischemic heart disease (IHD) was obtained and recorded. Serum uric acid level was estimated and compared with control group (healthy subjects).Results: Serum uric acid level was significantly higher among AMI patients (6.43±2.60) as compared to control group (4.05±0.95) (p&lt;0.001). Majority (46.7%) of the AMI patients had uric acid level of &gt;7.1 followed by 20% patients who had uric acid level between 4.5-5.9 (p&lt;0.001). Uric acid level was comparable between smoker and non-smokers (p=0.803), alcoholic and non-alcoholic (p=0.086), hypertensive and non-hypertensive (p=0.668), patients with and without diabetes (p=0.278) and patients with a history of IHD and without history of IHD (p=0.403).Conclusions: Serum uric acid may be useful for prognostication among those with pre-existing AMI.

The Importance of Electrocardiography in Pediatric Patients with Pulmonary Arterial Hypertension in Follow- up

Background: Right Ventricular (RV) hypertrophy is an adaptive response to chronic RV pressure overload in patients with pulmonary hypertension. We investigated the relationships between RV hypertrophy indicators, including electrocardiography, the percentage oxygen saturation (SaO2%), body mass index (BMI), and blood uric acid levels in patients with a biventricular structure followed up for Pulmonary Arterial Hypertension (PAH). Materials and Methods: This retrospective study included 33 patients with confirmed systemic PAH, according to the catheterization and a negative vascular reactivity test result. Patients with single-ventricle physiology and Down’s syndrome who had undergone surgery were excluded. The data of blood chemistry, hemogram, ECG, and SaO2% were collected, thus, the BMI was calculated. The patients were categorized according to SaO2 values ( 90% [n=19]), BMI (18.5 [n=17] kg/m2), PAH status (primary [n=13] vs. secondary [n=20]), and treatment regime (combination therapy [n=16] vs. monotherapy [n=17]), and the data were compared among the groups. Results: Patients with SaO2 values of 90% differed only in terms of blood uric acid level, which was significantly higher in the patients with SaO2 9 mm indicating impaired capacity. These measured markers can be used to follow-up patients with PAH.

A study of serum uric acid levels in chronic obstructive pulmonary disease

Hyperuricemia as a predictor in COPD and Exacerbation. The study aims to measure serum uric acid levels in patients with chronic obstructive pulmonary disease as a predictor. Materials and Methods: It is an observational study done on 50 COPD patients newly diagnosed or previously diagnosed. Serum uric acid level, chest x-ray and pulmonary function tests were performed with consent. Results: The mean normal Serum uric acid (mg/dl) was 4.86+ 1.6. The increased mean serum uric acid (Hyperuricemia) was 9.67+ 1.8. The mean serum urea and creatinine levels were 26.74+3.91 and 0.94+0.20. The FEV1% Predicted in Normal UAC – 51.8+18.6 and in cases of Hyperuricemia 53.4+16.7. FVC% Predicted in Normal UAC was 77.5+17.8 in cases of Hyperuricemia it was 76.5+18.5. Conclusion: The outcome of our study shows serum uric acid is cost-effective, easy and non-invasive and possibly suitable in assessing the patient disease severity, progression to exacerbation. Keywords: COPD, Serum uric acid, Hyperuricemia, Predictor.

English

English

ASSOCIATION OF SERUM SIALIC ACID AND SERUM URIC ACID LEVELS WITH FASTING BLOOD GLUCOSE LEVELS IN TYPE-2 DIABETES MELLITUS PATIENTS

Objectives: The objective of the study was to estimate the serum sialic acid and serum uric acid levels in patients with type-2 diabetes mellitus and non-diabetic individuals and determining the association of serum sialic acid and serum uric acid levels with fasting blood glucose levels in patients with type-2 diabetes mellitus and also in non-diabetic individuals.&#x0D; Methods: The study was a cross-sectional analysis where 70 individuals in the age group of 30–70 years participated during 6 months period. This included two groups, one for type-2 diabetes patients as cases and other non-diabetics as controls. In each group, 35 individuals participated. There were 15 males and 20 females in type-2 diabetic group and 16 males and 19 females in non-diabetic group. Fasting blood glucose, serum sialic acid, and serum uric acid were estimated in both the groups.&#x0D; Results: In this study, the serum sialic acid levels of type-2 diabetes mellitus were shown to be increased (76.60 ± 7.89) when compared to non-diabetics (39.66 ± 9.55) with a statistically significant, p &lt; 0.001. The serum uric acid concentrations were also found to be slightly elevated in type-2 diabetes mellitus (4.48 ± 0.79) when compared to non-diabetics (4.28 ± 0.89) with a statistically non-significant, p = 0.323.&#x0D; Conclusion: Based on this study, it is concluded that serum sialic acid and serum uric acid levels have been found to be positively associated with type- 2 diabetes mellitus in both men and women, indicating the risk of developing microvascular complications in those patients. Therefore, estimating the sialic acid and uric acid levels can aid in the early diagnosis and prevention of microvascular complications caused by type-2 diabetes mellitus.

Serum uric acid levels in patients with oral cancer, leukoplakia and submucous fibrosis: a cross-sectional study.

BackgroundThis cross-sectional cohort study aimed to assess the associations between the serum uric acid levels and oral leukoplakia (OL), submucous fibrosis (OSMF) and squamous cell carcinoma (OSCC), and to correlate these with the clinical and histopathological features of these lesions.MethodsFifty-two patients with oral potentially malignant disorders (OPMD) (25 OL and 27 OSMF cases) and 33 OSCC patients with complete clinical and histopathological characteristics were included. A healthy control group was also investigated. The serum uric acid concentration was assessed using the uricase method from a blood sample without hemolysis.ResultsThe level means of serum uric acid in the OL, OSMF and OSCC patients were 3.86±1.31, 5.65±0.85 and 4.99±1.34 mg/dL, respectively, compared to 5.16±0.97 mg/dL in the healthy controls.ConclusionsThe serum uric acid levels were reduced in the OL and OSCC patients but they were increased in the OSMF patients when compared to the healthy controls. No significant differences were seen in the clinical and histopathological features of the OL and OSMF patients. Future studies with larger sample sizes may improve the understanding of the contributory role of uric acid in the risk stratification of OPMDs. Although measuring the serum uric acid level involves a simple and economical assay, the data from this cross-sectional cohort does not support the clinical utility of evaluating the uric acid levels in OPMD and OSCC patients.

Relationship between life events and serum uric acid in patients with hyperuricemia

Objective To investigate the relationship between psychological stress related factors in life events and serum uric acid levels in patients with hyperuricemia. Methods The life events scale was used to qualitatively and quantitatively analyze the mental stimulation of 60 hyperuricemia patients. The laboratory analysis, as well as correlation analysis and multivariate regression analysis, were used to compare the general data and biochemical indicators of patients under different pressures. Results Patients with a total score of 20 or less on the life event scale were included in the low-pressure group, and the total score greater than 20 points in the high-pressure group. The highest frequency of positive and negative life events were outstanding achievement and stress in work and study. The frequency of gout attacks and cholesterol, triglyceride, serum creatinine, serum uric acid, and cortisol levels in the high-pressure group were significantly higher than those in the low-pressure group (P<0.05). The positive life event stimulation was positively correlated with cholesterol and triglyceride, and the negative life event stimulation was positively correlated with uric acid. In the multivariate linear regression analysis with serum uric acid as the dependent variable, the frequency of gout attacks and the stress group finally entered the regression model in the last year. The regression model had statistical significance F(2, 54)=27.765(P<0.01), adjusted R2=0.522. Conclusions In patients with hyperuricemia who are greatly stimulated in family life and work in life events, mental stress is related with elevated levels of cholesterol, triglycerides and serum uric acid. Elevated triglycerides and cholesterol are related to positive life events, and the rise of blood uric acid is related to negative life events. For patients with hyperuricemia, high-stress and frequent gouts are associated with higher levels of serum uric acid. Key words: Hyperuricemia; Life events; Psychological stress; Gout

English

English